Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Diprotin A
not selective for the enzyme
Ile cyanothiazolidide
not selective for the enzyme
Lys piperidide
not selective for the enzyme
Lys thiazolidide
not selective for the enzyme
N-(4-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butane-diamine dihydrochloride
-
threo-Ile thiazolidide
not selective for the enzyme
Val pyrrolidide
not selective for the enzyme
Val thiazolidide
not selective for the enzyme
(1R,S)-(2E)-2-(1-fluoro-2-[(2-phenylethyl)amino]ethylidene)cyclopentanecarbonitrile
-
IC50: 0.0361 mM, low inhibitory potential against EC 3.4.14.5
(1R,S)-(2E)-2-(1-fluoro-2-[(4-fluorobenzyl)amino]ethylidene)cyclopentanecarbonitrile
-
IC50: 0.0404 mM, low inhibitory potential against EC 3.4.14.5
(1R,S)-(2Z)-2-(1-fluoro-2-[(2-phenylethyl)amino]ethylidene)cyclopentanecarbonitrile
-
IC50: 0.0329 mM, low inhibitory potential against EC 3.4.14.5
(1R,S)-(2Z)-2-(1-fluoro-2-[(4-fluorobenzyl)amino]ethylidene)cyclopentanecarbonitrile
-
IC50: 0.0873 mM, low inhibitory potential against EC 3.4.14.5
(3S)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
-
-
(3S)-4-[(3aR,6aR)-hexahydrocyclopenta[b]pyrrol-1(2H)-yl]-4-oxobutane-1,3-diamine
-
AX8819, potent and selective inhibitor of DPP II
(3S)-N1-(4-chlorobenzyl)-4-(2-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
(3S)-N1-(4-chlorobenzyl)-4-(3-fluoropiperidin-1-yl)-4-oxobutane-1,3-diamine
(3S)-N1-(4-chlorobenzyl)-4-(3-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
-
IC50: 1.13 nM
(3S)-N1-(4-chlorobenzyl)-4-(4-fluoropiperidin-1-yl)-4-oxobutane-1,3-diamine
-
IC50: 0.39 nM
(3S)-N1-(4-chlorobenzyl)-4-(4-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
-
IC50: 0.55 nM
(3S)-N1-(4-chlorobenzyl)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
1-((2S)-2-amino-4-((4-chlorobenzyl)amino)butanoyl)piperidin-3-ol
-
IC50: 54.7 nM
1-((2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl)piperidin-4-ol
-
IC50: 113 nM
1-((2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl)piperidine-2-carbonitrile
-
IC50: 6.5 nM
1-([(2-phenylethyl)amino]acetyl)-2-pyrrolidinecarbonitrile
-
0.0163 mM
1-([(4-fluorobenzyl)amino]acetyl)-2-pyrrolidinecarbonitrile
-
IC50: 0.0255 mM
1-benzyl-N-(2-cyclohexylidene-2-fluoroethyl)-4-piperidinamine
-
IC50: 0.00104 mM, low inhibitory potential against EC 3.4.14.5
1-benzyl-N-(2-cyclohexylidene-2-fluoroethyl)piperidin-4-amine
-
-
1-benzyl-N-(2-cyclopentylidene-2-fluoroethyl)-4-piperidinamine
-
IC50: 0.0013 mM, low inhibitory potential against EC 3.4.14.5
1-benzyl-N-(2-oxo-2-piperidin-1-ylethyl)piperidin-4-amine
-
-
1-benzyl-N-[2-oxo-2-(1-piperidinyl)ethyl]-4-piperidinamine
-
IC50: 0.0031 mM, low inhibitory potential against EC 3.4.14.5
1-[(1-adamantylamino)acetyl]-2-pyrrolidinecarbonitrile
-
IC50: 0.1335 mM
1-[(2S)-2-amino-4-(benzylamino)butanoyl]piperidine-2-carbonitrile
-
IC50: 4.0 nM
1-[(2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl]piperidin-3-ol
-
IC50: 54.7 nM
1-[(2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl]piperidin-4-ol
-
IC50: 113 nM
1-[(2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl]piperidine-2-carbonitrile
-
IC50: 6.5 nM
3-((3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl)aminomethyl)-benzonitrile
-
IC50: 2.7 nM
4-oxo-4-(1-piperidinyl)-N1 -(4-piperidinyl)-1,3-(S)-butanedi-amine
-
IC50: 85 nM
4-oxo-4-(1-piperidinyl)-N1-(2-thienylmethyl)-1,3-(S)-butanediamine
-
IC50: 0.8 nM
4-oxo-4-(1-piperidinyl)-N1-(4-pyridinylmethyl)-1,3-(S)-butanediamine
-
IC50: 0.75 nM
4-oxo-4-(1-piperidinyl)-N3-(4-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.017 mM
4-oxo-N1-(2-phenylethyl)-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.9 nM
4-oxo-N1-(3-phenylpropyl)-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.91 nM
4-oxo-N1-phenyl-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.0015 mM
6-((3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl)amino)nicotinonitrile
-
IC50: 0.0046 mM
Ala-PSI[CS-N]-pyrrolidine
-
competitive
Ala-PSI[CS-N]-thiazolidine
-
competitive
Ala-pyrrolidine
-
competitive
Ala-thiazolidine
-
competitive
benzyl 4-[(2-cyclohexylidene-2-fluoroethyl)amino]-1-piperidinecarboxylate
-
IC50: 0.0128 mM, low inhibitory potential against EC 3.4.14.5
diisopropyl fluorophosphate
-
-
Ile-PSI[CS-N]-pyrrolidine
-
competitive
Ile-PSI[CS-N]-thiazolidine
-
competitive
Ile-pyrrolidine
-
competitive
Ile-thiazolidine
-
competitive
N-(1,3-benzodioxol-5-ylmethyl)-2-cyclohexylidene-2-fluoroethanamine
-
IC50: 0.0129 mM, low inhibitory potential against EC 3.4.14.5
N-(1,3-benzodioxol-5-ylmethyl)-2-cyclopentylideneethanamine
N-(2-cyclohexylidene-2-fluoroethyl)-1-adamantanamine
-
IC50: 0.0913 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclohexylidene-2-fluoroethyl)-4-piperidinamine
-
IC50: 0.0042 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclohexylidene-2-fluoroethyl)-N-(2-phenylethyl)-amine
-
IC50: 0.011 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclohexylidene-2-fluoroethyl)-N-(4-fluorobenzyl)-amine
-
IC50: 0.0219 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclohexylidene-2-fluoroethyl)-N-(4-methoxybenzyl)amine
-
IC50: 0.0134 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclohexylidene-2-fluoroethyl)aniline
-
IC50: 0.1 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclohexylidene-2-fluoroethyl)cyclohexanamine
-
IC50: 0.5 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-phenylethyl)amine
-
IC50: 0.0272 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-pyridinylethyl)amine
N-(2-cyclopentylidene-2-fluoroethyl)-N-(4-fluorobenzyl)amine
-
IC50: 0.0108 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylidene-2-fluoroethyl)-N-(4-methoxy-benzyl)amine
-
IC50: 0.0155 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylidene-2-fluoroethyl)cyclohexanamine
-
IC50: 0.09 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylideneethyl)cyclohexanamine
N-(4-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butane-diamine dihydrochloride
-
-
N-benzyl-2-cyclohexylidene-2-fluoroethanamine
-
IC50: 0.034 mM, low inhibitory potential against EC 3.4.14.5
N-benzyl-2-cyclopentylidene-2-fluoroethanamine
-
IC50: 0.0378 mM, low inhibitory potential against EC 3.4.14.5
N-benzyl-2-cyclopentylideneethanamine
N-benzyl-2-oxo-2-(1-piperidinyl)ethaneamine
-
IC50: 0.397 mM, low inhibitory potential against EC 3.4.14.5
N-benzyl-2-oxo-2-(1-pyrrolidinyl)ethaneamine
-
IC50: 0.5 mM
N-benzyl-2-thioxo-2-(1-piperidinyl)ethaneamine
-
IC50: 0.0484 mM, low inhibitory potential against EC 3.4.14.5
N-cyclohexyl-2-oxo-2-(1-piperidinyl)ethaneamine
-
IC50: 0.177 mM, low inhibitory potential against EC 3.4.14.5
N-cyclohexyl-2-oxo-2-(1-pyrrolidinyl)ethaneamine
-
IC50: 0.276 mM
N-cyclohexyl-2-thioxo-2-(1-piperidinyl)ethaneamine
-
IC50: 0.069 mM, low inhibitory potential against EC 3.4.14.5
N-cyclohexyl-2-thioxo-2-(1-pyrrolidinyl)ethaneamine
-
IC50: 0.092 mM, low inhibitory potential against EC 3.4.14.5
N-piperonyl-2-oxo-2-(1-piperidinyl)ethaneamine
-
IC50: 0.052 mM, low inhibitory potential against EC 3.4.14.5
N-piperonyl-2-oxo-2-(1-pyrrolidinyl)ethaneamine
-
IC50: 0.063 mM, low inhibitory potential against EC 3.4.14.5
N-piperonyl-2-thioxo-2-(1-piperidinyl)ethaneamine
-
IC50: 0.042 mM, low inhibitory potential against EC 3.4.14.5
N-piperonyl-2-thioxo-2-(1-pyrrolidinyl)ethaneamine
-
IC50: 0.067 mM, low inhibitory potential against EC 3.4.14.5
N-[3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl]acetamide
-
IC50: 0.0015 mM
N-[3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl]guanidine bis-(trifluoroacetate)
-
IC50: 0.0018 mM
N-[3-amino-1-(S)-(1-piperidinylcarbonyl)propyl]guanidine bis-(trifluoroacetate)
-
IC50: 0.0074 mM
N-[3-amino-4-oxo-4-(1-piperidinyl)butyl]benzamide
-
IC50: 0.0074 mM
N1 -(2-cyclopentylidene-2-fluoroethyl)-N3,N3-dimethyl-1,3-propanediamine
-
IC50: 0.0537 mM, low inhibitory potential against EC 3.4.14.5
N1 -(4-methoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.66 nM
N1,N1-di(4-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 4.2 nM
N1,N1-dibenzyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.6 nM
N1-(1-naphthylmethyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.31 nM
N1-(2,4-dimethoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 2.7 nM
N1-(2-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.23 nM
N1-(2-cyclohexylidene-2-fluoroethyl)-N3,N3-dimethyl-1,3-propanediamine
-
IC50: 0.0546 mM, low inhibitory potential against EC 3.4.14.5
N1-(2-methoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.85 nM
N1-(2-naphthylmethyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.1 nM
N1-(3-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.34 nM
N1-(3-methoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.77 nM
N1-(3-nitro-2-pyridinyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.0235 mM
N1-(4-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.48 nM
N1-(4-chlorobenzyl)-N1-methyl-4-oxo-4-(1-piperidinyl)-1,3-butanediamine
-
IC50: 0.22 nm
N1-(cyclohexylmethyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 1.1 nM
N1-benzyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 2.03 nM
N1-cyclohexyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 18.6 nM
N1-[2-(benzyloxy)benzyl]-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.39 nM
N1-[4-(benzyloxy)benzyl]-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
-
IC50: 0.41 nM
N2-cyclopentyl-N-[(diphenoxyphosphoryl)(phenyl)methyl]glycinamide
-
-
N3-benzyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine dihydrobromide
-
IC50: 0.0125 mM
Phe-PSI[CS-N]-pyrrolidine
-
competitive
Phe-PSI[CS-N]-thiazolidine
-
competitive
Phe-pyrrolidine
-
competitive
Phe-thiazolidine
-
competitive
phenylmethylsulfonyl fluoride
-
-
Val-PSI[CS-N]-pyrrolidine
-
competitive
Val-PSI[CS-N]-thiazolidine
-
competitive
Val-pyrrolidine
-
competitive
Val-thiazolidine
-
competitive
[(1R)-1-[[(2S)-2,4-diaminobutanoyl]amino]pentyl]boronic acid
-
-
additional information
-
isomerization of the thiazolidine derivatives
-
(3S)-N1-(4-chlorobenzyl)-4-(2-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
-
IC50: 2.3 mM
(3S)-N1-(4-chlorobenzyl)-4-(2-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
-
IC50: 2.3 nM
(3S)-N1-(4-chlorobenzyl)-4-(3-fluoropiperidin-1-yl)-4-oxobutane-1,3-diamine
-
0.62 nM
(3S)-N1-(4-chlorobenzyl)-4-(3-fluoropiperidin-1-yl)-4-oxobutane-1,3-diamine
-
IC50: 0.62 nM
(3S)-N1-(4-chlorobenzyl)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
-
IC50: 1.1 nM
(3S)-N1-(4-chlorobenzyl)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
-
UAMC00039, potent and specific inhibitor
N-(1,3-benzodioxol-5-ylmethyl)-2-cyclopentylideneethanamine
-
0.0075 mM
N-(1,3-benzodioxol-5-ylmethyl)-2-cyclopentylideneethanamine
-
IC50: 0.0075 mM, low inhibitory potential against EC 3.4.14.5, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-pyridinylethyl)amine
-
IC50: 0.0096 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-pyridinylethyl)amine
-
IC50: 0.0157 mM, low inhibitory potential against EC 3.4.14.5
N-(2-cyclopentylideneethyl)cyclohexanamine
-
IC50: 0.062 mM
N-(2-cyclopentylideneethyl)cyclohexanamine
-
IC50: 0.062 mM, low inhibitory potential against EC 3.4.14.5, low inhibitory potential against EC 3.4.14.5
N-benzyl-2-cyclopentylideneethanamine
-
IC50: 0.026 mM
N-benzyl-2-cyclopentylideneethanamine
-
IC50: 0.026 mM, low inhibitory potential against EC 3.4.14.5, low inhibitory potential against EC 3.4.14.5
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acquired Immunodeficiency Syndrome
Successful immunomodulating in AIDS patients with ursodeoxycholic acid--a pilot study.
Adenocarcinoma
Activation of EDTA-resistant gelatinases in malignant human tumors.
Adenocarcinoma
Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
Adenocarcinoma
Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Adenocarcinoma
Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer.
Adenocarcinoma
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Adenocarcinoma, Follicular
Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines.
Adenocarcinoma, Follicular
Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor.
Albuminuria
Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
Albuminuria
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.
Alzheimer Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Anemia, Refractory, with Excess of Blasts
[Serum proteomics in patients with RAEB myelodysplastic syndromes.]
Arthralgia
Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis.
Arthritis
Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis.
Arthritis, Rheumatoid
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythematosus and rheumatoid arthritis.
Arthritis, Rheumatoid
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Comment on: levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.
Arthritis, Rheumatoid
Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis.
Arthritis, Rheumatoid
Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.
Arthritis, Rheumatoid
Lysosomal peptidases and glycosidases in rheumatoid arthritis.
Arthritis, Rheumatoid
Role of Fibroblast Activation Protein Alpha in Fibroblast-like Synoviocytes of Rheumatoid Arthritis.
Asthma
A genome-wide association study on African-ancestry populations for asthma.
Asthma
Asthma severity and genetics in Taiwan.
Asthma
Diversity of asthma: evolving concepts of pathophysiology and lessons from genetics.
Asthma
DPP10 modulates Kv4-mediated A-type potassium channels.
Asthma
Genetic aspects of the etiology and treatment of asthma.
Asthma
Increased angiogenic factors in exhaled breath condensate of children with severe asthma - New markers of disease progression?
Asthma
Inhibition of airway inflammation and remodeling by sitagliptin in murine chronic asthma.
Asthma
Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms.
Atherosclerosis
Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
Atherosclerosis
Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice.
Atherosclerosis
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.
Atherosclerosis
The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice.
Atrial Fibrillation
Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.
Biliary Atresia
Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence.
Brain Injuries
Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage.
Breast Neoplasms
Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer.
Breast Neoplasms
Evaluation of seprase activity.
Breast Neoplasms
Identification of Dipeptidyl Peptidase (DPP) Family Genes in Clinical Breast Cancer Patients via an Integrated Bioinformatics Approach.
Breast Neoplasms
Macrophages are exploited from an innate wound healing response to facilitate cancer metastasis.
Breast Neoplasms
Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling.
Breast Neoplasms
Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer.
Breast Neoplasms
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
Breast Neoplasms
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Carcinogenesis
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Carcinogenesis
Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10-dimethyl-1,2-benzanthracene.
Carcinoma
Activation of EDTA-resistant gelatinases in malignant human tumors.
Carcinoma
Alteration in dipeptidyl peptidase activities in cultured human carcinoma cells.
Carcinoma
Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
Carcinoma
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Carcinoma
Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Carcinoma
Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm.
Carcinoma
Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.
Carcinoma
Lysosomal dipeptidyl-peptidases I and II in human squamous cell lung carcinoma and lung parenchyma.
Carcinoma
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
Carcinoma
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Carcinoma
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Carcinoma
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Carcinoma, Ductal
Activation of EDTA-resistant gelatinases in malignant human tumors.
Carcinoma, Ductal
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
Carcinoma, Ductal
Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.
Carcinoma, Ovarian Epithelial
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Carcinoma, Ovarian Epithelial
Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.
Carcinoma, Signet Ring Cell
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Carcinoma, Squamous Cell
Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV.
Carcinoma, Squamous Cell
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Cardiomyopathies
Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.
Cardiovascular Diseases
Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study.
Cardiovascular Diseases
Cotreatment with the ?-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Cataract
Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats.
Cervical Intraepithelial Neoplasia
Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm.
Cholestasis
Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence.
Chronic Periodontitis
Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid. A comparison of levels before and after basic periodontal treatment of chronic periodontitis patients.
Chronic Periodontitis
Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid: a comparison of levels before and after periodontal surgery in chronic periodontitis patients.
Chronic Periodontitis
Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid: correlation with clinical parameters in untreated chronic periodontitis patients.
Chronic Periodontitis
Correlation between gingivain/gingipain and bacterial dipeptidyl peptidase activity in gingival crevicular fluid and periodontal attachment loss in chronic periodontitis patients. A 2-year longitudinal study.
Chronic Periodontitis
Correlation between gingival crevicular fluid dipeptidyl peptidase II and IV activity and periodontal attachment loss. A 2-year longitudinal study in chronic periodontitis patients.
Chronic Periodontitis
Histochemical and immunocytochemical localization of dipeptidyl peptidases II and IV in human gingiva.
Colitis
Colitis development and resolution in mice with target deletion of dipeptidyl peptidase IV/CD26.
Colitis
Dipeptidyl peptidase expression during experimental colitis in mice.
Colitis
Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice.
Colitis
Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice.
Colonic Neoplasms
Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation.
Colonic Neoplasms
Inhibition of growth and induction of alkaline phosphatase in colon cancer cells by flavonols and flavonol glycosides.
Colorectal Neoplasms
'Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer'.
Colorectal Neoplasms
Colorectal cancer cell intrinsic fibroblast activation protein alpha binds to Enolase1 and activates NF-?B pathway to promote metastasis.
Colorectal Neoplasms
Diagnostic utility of serum dipeptidyl peptidase (DPP- IV) /CD26 as a serum marker in Egyptian patients with colorectal cancer.
Colorectal Neoplasms
Dipeptidyl peptidase 10, a novel prognostic marker in colorectal cancer.
Colorectal Neoplasms
Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer.
Colorectal Neoplasms
Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer.
Coronary Stenosis
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.
Coronavirus Infections
Acute respiratory infection in human dipeptidyl peptidase 4-transgenic mice infected with Middle East respiratory syndrome coronavirus.
Coronavirus Infections
Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus.
COVID-19
Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review.
COVID-19
Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands.
Crohn Disease
Stable and scalable SERS tags conjugated with neutravidin for the detection of fibroblast activation protein (FAP) in primary fibroblasts.
Crohn Disease
The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease.
Dementia
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Diabetes Complications
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Diabetes Mellitus
A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
Diabetes Mellitus
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
Diabetes Mellitus
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Diabetes Mellitus
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Diabetes Mellitus
Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Diabetes Mellitus
Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Diabetes Mellitus
Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Diabetes Mellitus
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
Diabetes Mellitus
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Diabetes Mellitus
Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Diabetes Mellitus
Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Diabetes Mellitus
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Diabetes Mellitus
Efficacy and safety of Dipeptidyl Peptidase-4 Inhibitors in kidney transplant recipients with Post-transplant diabetes mellitus (PTDM)-a systematic review and Meta-Analysis.
Diabetes Mellitus
Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Diabetes Mellitus
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism.
Diabetes Mellitus
Glucose dependent insulinotropic polypeptide and dipeptidyl peptidase inhibitors: Their roles in management of type 2 diabetes mellitus.
Diabetes Mellitus
Inhibition of dipeptidyl peptidase activity by flavonol glycosides of guava (Psidium guajava L.): a key to the beneficial effects of guava in type II diabetes mellitus.
Diabetes Mellitus
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
Diabetes Mellitus
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus
Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
Diabetes Mellitus
New therapies for diabetes.
Diabetes Mellitus
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Diabetes Mellitus
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Diabetes Mellitus
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Diabetes Mellitus
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Diabetes Mellitus
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus
Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
Diabetes Mellitus
Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives.
Diabetes Mellitus
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Diabetes Mellitus
Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Diabetes Mellitus
The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1?-induced endothelial inflammation and monocytes attachment.
Diabetes Mellitus
The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.
Diabetes Mellitus
Trelagliptin: First Global Approval.
Diabetes Mellitus
Type 2 diabetes mellitus in children and adolescents.
Diabetes Mellitus
ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors
Diabetes Mellitus, Type 2
A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors.
Diabetes Mellitus, Type 2
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Diabetes Mellitus, Type 2
Acute and long-term effects of saxagliptin on a set of cardiovascular targets measured at fasting and post-prandially in obese patients with impaired glucose tolerance: A placebo-controlled study.
Diabetes Mellitus, Type 2
Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.
Diabetes Mellitus, Type 2
Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors.
Diabetes Mellitus, Type 2
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Diabetes Mellitus, Type 2
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.
Diabetes Mellitus, Type 2
Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
Diabetes Mellitus, Type 2
Cellular glucose availability and glucagon-like peptide-1.
Diabetes Mellitus, Type 2
Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice.
Diabetes Mellitus, Type 2
Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients.
Diabetes Mellitus, Type 2
Clinical pharmacokinetics and pharmacodynamics of linagliptin.
Diabetes Mellitus, Type 2
Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study.
Diabetes Mellitus, Type 2
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance through the CXCL12/CXCR4/mTOR/TGF? Signaling Pathway in Breast Cancer Cells.
Diabetes Mellitus, Type 2
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.
Diabetes Mellitus, Type 2
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.
Diabetes Mellitus, Type 2
Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Diabetes Mellitus, Type 2
Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
Diabetes Mellitus, Type 2
Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.
Diabetes Mellitus, Type 2
Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Diabetes Mellitus, Type 2
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Diabetes Mellitus, Type 2
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
Diabetes Mellitus, Type 2
Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.
Diabetes Mellitus, Type 2
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies.
Diabetes Mellitus, Type 2
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.
Diabetes Mellitus, Type 2
Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study.
Diabetes Mellitus, Type 2
Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males.
Diabetes Mellitus, Type 2
Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Diabetes Mellitus, Type 2
Fortification of Maize Tortilla with an Optimized Chickpea Hydrolysate and Its Effect on DPPIV Inhibition Capacity and Physicochemical Characteristics.
Diabetes Mellitus, Type 2
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism.
Diabetes Mellitus, Type 2
Glucose dependent insulinotropic polypeptide and dipeptidyl peptidase inhibitors: Their roles in management of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study.
Diabetes Mellitus, Type 2
Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
Diabetes Mellitus, Type 2
Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among Moringa oleifera Phytochemicals by Virtual Screening, Molecular Docking Analysis, ADME/T-Based Prediction, and In Vitro Analyses.
Diabetes Mellitus, Type 2
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
Diabetes Mellitus, Type 2
Incretins and Their Endocrine and Metabolic Functions.
Diabetes Mellitus, Type 2
Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride.
Diabetes Mellitus, Type 2
Inhibition of Dipeptidyl Peptidase (DPP)-IV and ?-Glucosidase Activities by Pepsin-Treated Whey Proteins.
Diabetes Mellitus, Type 2
Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins.
Diabetes Mellitus, Type 2
Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.
Diabetes Mellitus, Type 2
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Diabetes Mellitus, Type 2
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
Diabetes Mellitus, Type 2
Linagliptin: an update of its use in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
Diabetes Mellitus, Type 2
New therapies for diabetes.
Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Diabetes Mellitus, Type 2
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Diabetes Mellitus, Type 2
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Diabetes Mellitus, Type 2
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Diabetes Mellitus, Type 2
Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
Diabetes Mellitus, Type 2
Physiologically Based Pharmacokinetic Model of the DPP-4 Inhibitor Linagliptin to Describe its Nonlinear Pharmacokinetics in Humans.
Diabetes Mellitus, Type 2
Phytochemical Analysis, Network Pharmacology and in Silico Investigations on Anacamptis pyramidalis Tuber Extracts.
Diabetes Mellitus, Type 2
Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
Diabetes Mellitus, Type 2
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients.
Diabetes Mellitus, Type 2
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research.
Diabetes Mellitus, Type 2
Renoprotective Effects of DPP-4 Inhibitors.
Diabetes Mellitus, Type 2
Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives.
Diabetes Mellitus, Type 2
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
Diabetes Mellitus, Type 2
Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo.
Diabetes Mellitus, Type 2
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Diabetes Mellitus, Type 2
Sitagliptin (DPP-4 Inhibitor)-induced Rheumatoid Arthritis in Type 2 Diabetes Mellitus: A Case Report.
Diabetes Mellitus, Type 2
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34(+)CXCR4 (+) cells in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.
Diabetes Mellitus, Type 2
Systematic analysis of a dipeptide library for inhibitor development using human dipeptidyl peptidase IV produced by a Saccharomyces cerevisiae expression system.
Diabetes Mellitus, Type 2
Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Diabetes Mellitus, Type 2
The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1?-induced endothelial inflammation and monocytes attachment.
Diabetes Mellitus, Type 2
The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.
Diabetes Mellitus, Type 2
The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.
Diabetes Mellitus, Type 2
The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.
Diabetes Mellitus, Type 2
Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
Diabetes Mellitus, Type 2
Trelagliptin: First Global Approval.
Diabetes Mellitus, Type 2
Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Diabetes Mellitus, Type 2
Type 2 diabetes mellitus in children and adolescents.
Diabetes Mellitus, Type 2
ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
[Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
Diabetes Mellitus, Type 2
[Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors].
Diabetic Nephropathies
Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in ?-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study.
Diabetic Nephropathies
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
Diabetic Nephropathies
Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
Diabetic Nephropathies
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Diabetic Nephropathies
The Role of Dipeptidyl Peptidase - 4 Inhibitors in Diabetic Kidney Disease.
Diabetic Retinopathy
Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
dipeptidyl-peptidase i deficiency
Nemaline myopathy. Evidence of dipeptidyl peptidase I deficiency.
Fatigue Syndrome, Chronic
Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.
Gallstones
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.
Gingivitis
A simple, combined fluorogenic and chromogenic method for the assay of proteases in gingival crevicular fluid.
Gingivitis
Detection of cathepsin B- and L-, elastase-, tryptase-, trypsin-, and dipeptidyl peptidase IV-like activities in crevicular fluid from gingivitis and periodontitis patients with peptidyl derivatives of 7-amino-4-trifluoromethyl coumarin.
Glioblastoma
Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.
Glioma
Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.
Glioma
Quaternary benzo[c]phenanthridine alkaloids as inhibitors of dipeptidyl peptidase IV-like activity baring enzymes in human blood plasma and glioma cell lines.
Glomerulonephritis, Membranous
Role of dipeptidyl peptidase IV (gp 108) in passive Heymann nephritis. Use of dipeptidyl peptidase IV-deficient rats.
Heart Arrest
Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome.
Heart Failure
Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure.
Heart Failure
Glycemia Lowering and Risk for Heart Failure: Recent Evidence from Studies of Dipeptidyl Peptidase Inhibition.
Herpes Zoster
Dipeptidyl Peptidase IV-Activated Prodrugs of Anti-Varicella Zoster Virus Bicyclic Nucleoside Analogues Containing Different Self-Cleavage Spacer Systems.
Herpes Zoster
Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
Huntington Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Hyperglycemia
Cotreatment with the ?-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Hyperglycemia
Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
Hyperglycemia
Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride.
Hyperglycemia
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Hyperglycemia
Potential for Combination of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Co-Transporter-2 Inhibitors for the Treatment of Type 2 Diabetes.
Hypertension
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Hypertension
Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium.
Hypertension
The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.
Hypoglycemia
Clinical and economical consequences of the combination of metformin with dipeptidyl peptidase inhibitors in type 2 diabetes patients.
Hypoglycemia
Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Hypoglycemia
Linagliptin use in older individuals with type 2 diabetes.
Hypoglycemia
Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations.
Hypoglycemia
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
Hypoglycemia
The Place of GLP-1-Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists.
Hypotension
Ophidian envenomation strategies and the role of purines.
Immune System Diseases
Activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in human gingiva with chronic marginal periodontitis.
Infections
Acute respiratory infection in human dipeptidyl peptidase 4-transgenic mice infected with Middle East respiratory syndrome coronavirus.
Infections
Localization and activity of various lysosomal proteases in Leishmania amazonensis-infected macrophages.
Infections
Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review.
Infections
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection.
Infections
Short-term dipeptidyl peptidase-4 inhibitor use increases the risk of herpes zoster infection in Asian patients with diabetes.
Infections
[Localization and activity of different lysosomal proteases in rat macrophages infected by Leishmania amazonensis]
Insulin Resistance
Antidiabetic potential of dietary polyphenols: A mechanistic review.
Insulin Resistance
Effect of thymoquinone on high fat diet and STZ-induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies.
Insulin Resistance
Effects of short-term calorie restriction on circulating DPP-4/sCD26 concentrations and body composition in patients with type 2 diabetes.
Insulin Resistance
Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
Insulin Resistance
Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.
Insulin Resistance
Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Insulin Resistance
The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin has the Capacity to Repair ?-Cell Dysfunction and Insulin Resistance.
Insulin Resistance
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Insulinoma
A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Keloid
Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
Leukemia, Lymphocytic, Chronic, B-Cell
Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Possible prognostic significance of the assessment of dipeptidylpeptidase II in peripheral blood lymphocytes of patients with chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Problems with prognostic criteria in patients with chronic lymphocytic leukemia with special reference to DPP II assessment.
Leukoplakia
Low expression of angiotensinogen and dipeptidyl peptidase 1 in saliva of patients with proliferative verrucous leukoplakia.
Lewy Body Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Liver Cirrhosis
Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.
Liver Cirrhosis, Biliary
Successful immunomodulating in AIDS patients with ursodeoxycholic acid--a pilot study.
Liver Neoplasms
Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells.
Lung Injury
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Lupus Nephritis
Redistribution of glomerular dipeptidyl peptidase type IV in experimental lupus nephritis. Demonstration of decreased enzyme activity at the ultrastructural level.
Lymphatic Metastasis
'Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer'.
Lymphatic Metastasis
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Lymphatic Metastasis
Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer.
Lymphatic Metastasis
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Melanoma
A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells.
Melanoma
Activation of EDTA-resistant gelatinases in malignant human tumors.
Melanoma
Dipeptidyl peptidase II is not a marker for progression in melanoma.
Melanoma
Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform.
Melanoma
Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.
Melanoma
Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.
Melanoma
Molecular cloning of seprase: a serine integral membrane protease from human melanoma.
Melanoma
Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton.
Melanoma
Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.
Melanoma
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Melanoma
Transcriptional Regulation of Seprase in Invasive Melanoma Cells by Transforming Growth Factor-? Signaling.
Melanoma
Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases.
Meningioma
Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
Metabolic Syndrome
The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.
Mouth Neoplasms
Decreased expression and release of dipeptidyl peptidase IV (CD26) in cultured peripheral blood T lymphocytes of oral cancer patients.
Mouth Neoplasms
Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients.
Mouth Neoplasms
Serum dipeptidyl peptidase (DPP) IV activities in oral cancer patients.
Mouth Neoplasms
Serum dipeptidyl peptidase activities as a possible marker of oral cancer.
Muscular Dystrophies
Muscle breakdown and lysosomal activation (biochemistry).
Myocardial Infarction
Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI.
Myocardial Infarction
Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
Myocardial Infarction
Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction.
Myocardial Infarction
Genetic ablation of fibroblast activation protein alpha attenuates left ventricular dilation after myocardial infarction.
Myocardial Infarction
Reduced post-operative DPP4 activity associated with worse patient outcome after cardiac surgery.
Myocardial Ischemia
[Expression of FAPalpha and TGF-beta1 in sudden deaths due to acute myocardial ischemia].
Myocarditis
Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis.
Myopathies, Nemaline
Nemaline myopathy. Evidence of dipeptidyl peptidase I deficiency.
Neoplasm Metastasis
'Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer'.
Neoplasm Metastasis
Colorectal cancer cell intrinsic fibroblast activation protein alpha binds to Enolase1 and activates NF-?B pathway to promote metastasis.
Neoplasm Metastasis
Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Neoplasm Metastasis
Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor.
Neoplasm Metastasis
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Neoplasm Metastasis
Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Neoplasm Metastasis
Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm.
Neoplasm Metastasis
Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer.
Neoplasm Metastasis
Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer?
Neoplasm Metastasis
Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling.
Neoplasm Metastasis
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
Neoplasm Metastasis
Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.
Neoplasm Metastasis
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Neoplasm Metastasis
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha.
Neoplasm Metastasis
Targeting FAP?-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
Neoplasm Metastasis
The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.
Neoplasm Metastasis
The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness.
Neoplasm Metastasis
Transcriptional Regulation of Seprase in Invasive Melanoma Cells by Transforming Growth Factor-? Signaling.
Neoplasm Micrometastasis
The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness.
Neoplasms
'Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer'.
Neoplasms
A combination of serum markers for the early detection of colorectal cancer.
Neoplasms
A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein.
Neoplasms
Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth.
Neoplasms
Activation of EDTA-resistant gelatinases in malignant human tumors.
Neoplasms
Alteration in dipeptidyl peptidase activities in cultured human carcinoma cells.
Neoplasms
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Neoplasms
Cancer-associated fibroblasts-derived exosomes-mediated transfer of LINC00355 regulates bladder cancer cell proliferation and invasion.
Neoplasms
Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8.
Neoplasms
Colorectal cancer cell intrinsic fibroblast activation protein alpha binds to Enolase1 and activates NF-?B pathway to promote metastasis.
Neoplasms
Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer.
Neoplasms
Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines.
Neoplasms
Development of a Cross-Reactive Monoclonal Antibody for Detecting the Tumor Stroma.
Neoplasms
Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
Neoplasms
Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor.
Neoplasms
Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Neoplasms
Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity.
Neoplasms
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.
Neoplasms
DPPIV and seprase in cancer invasion and angiogenesis.
Neoplasms
Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells.
Neoplasms
Evaluation of seprase activity.
Neoplasms
Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia.
Neoplasms
Expression and role of the cell surface protease seprase/fibroblast activation protein-? (FAP-?) in astroglial tumors.
Neoplasms
Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm.
Neoplasms
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts.
Neoplasms
Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.
Neoplasms
In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
Neoplasms
Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
Neoplasms
Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer.
Neoplasms
Increased tissue and circulating levels of dipeptidyl peptidase-IV enzymatic activity in patients with pancreatic ductal adenocarcinoma.
Neoplasms
Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth.
Neoplasms
Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi.
Neoplasms
Lysosomal dipeptidyl-peptidases I and II in human squamous cell lung carcinoma and lung parenchyma.
Neoplasms
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.
Neoplasms
Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma.
Neoplasms
New trends in anti-cancer therapy: combining conventional chemotherapeutics with novel immunomodulators.
Neoplasms
Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cells.
Neoplasms
Pediatric phase I trial design using maximum target inhibition as the primary endpoint.
Neoplasms
Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer.
Neoplasms
Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Neoplasms
Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer.
Neoplasms
Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells.
Neoplasms
Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers.
Neoplasms
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Neoplasms
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China.
Neoplasms
Seprase: an overview of an important matrix serine protease.
Neoplasms
Serum activities of dipeptidyl-aminopeptidase II and dipeptidyl-aminopeptidase IV in tumor-bearing animals and in cancer patients.
Neoplasms
Serum dipeptidyl peptidase (DPP) IV activities in oral cancer patients.
Neoplasms
Simultaneous engagement of tumor and stroma targeting antibodies by engineered NK-92 cells expressing CD64 controls prostate cancer growth.
Neoplasms
Species-specific real-time RT-PCR analysis of expression of stromal cell genes in a tumor xenotransplantation model in mice.
Neoplasms
Stromal Expression of Fibroblast Activation Protein Alpha (FAP) Predicts Platinum Resistance and Shorter Recurrence in patients with Epithelial Ovarian Cancer.
Neoplasms
Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha.
Neoplasms
Supplementation of endogenous Ahr ligands reverses insulin resistance and associated inflammation in an insulin-dependent diabetic mouse model.
Neoplasms
Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma-Associations with tumor phenotype and survival.
Neoplasms
Targeting of cancer?associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment.
Neoplasms
The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.
Neoplasms
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Neoplasms
The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23.
Neoplasms
The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness.
Neoplasms
The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer.
Neoplasms
The stromal cell-surface protease fibroblast activation protein-? localizes to lipid rafts and is recruited to invadopodia.
Neoplasms
Transcriptional Regulation of Seprase in Invasive Melanoma Cells by Transforming Growth Factor-? Signaling.
Neoplasms
TWIST1 promotes invasion through mesenchymal change in human glioblastoma.
Neoplasms
[FIBROBLAST ACTIVATION PROTEIN (FAP) AS A POSSIBLE TARGET OF THE ANTITUMOR STRATEGY.]
Neoplasms, Glandular and Epithelial
Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.
Neoplastic Cells, Circulating
Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule.
Neurodegenerative Diseases
Dipeptidyl peptidase 10 (DPP10(789)): a voltage gated potassium channel associated protein is abnormally expressed in Alzheimer's and other neurodegenerative diseases.
Neurodegenerative Diseases
Saxagliptin: a novel antiparkinsonian approach.
Non-alcoholic Fatty Liver Disease
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Non-alcoholic Fatty Liver Disease
[Serum dipeptidyl peptidase N levels in obese children with nonalcoholic fatty liver disease].
Obesity
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.
Obesity
Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: Possible implications for the hypothalamic neuropeptidergic system.
Obesity
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism.
Osteoarthritis
Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Activities of dipeptidyl peptidase II, dipeptidyl peptidase IV, prolyl endopeptidase, and collagenase-like peptidase in synovial membrane from patients with rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Cysteine and serine proteases of synovial tissue in rheumatoid arthritis and osteoarthritis.
Osteoarthritis
Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis.
Osteoarthritis
Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis.
Otitis Media
Presence of dipeptidyl peptidase II, dipeptidyl peptidase IV, and prolyl endopeptidase in effusion from patients with serous otitis media.
Otitis Media with Effusion
Presence of dipeptidyl peptidase II, dipeptidyl peptidase IV, and prolyl endopeptidase in effusion from patients with serous otitis media.
Ovarian Neoplasms
Expression levels of seprase/FAP? and DPPIV/CD26 in epithelial ovarian carcinoma.
Ovarian Neoplasms
Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Ovarian Neoplasms
Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cells.
Ovarian Neoplasms
Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.
Pancreatic Neoplasms
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Pancreatitis
Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Parkinson Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Parkinson Disease
Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's disease.
Parkinson Disease
Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.
Pemphigoid, Bullous
Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors: A Case/Non-Case study in the French Pharmacovigilance Database.
Periodontal Attachment Loss
Correlation between gingivain/gingipain and bacterial dipeptidyl peptidase activity in gingival crevicular fluid and periodontal attachment loss in chronic periodontitis patients. A 2-year longitudinal study.
Periodontal Attachment Loss
Correlation between gingival crevicular fluid dipeptidyl peptidase II and IV activity and periodontal attachment loss. A 2-year longitudinal study in chronic periodontitis patients.
Periodontal Diseases
Distribution of dipeptidyl peptidase (DPP) 4, DPP5, DPP7, and DPP11 in human oral microbiota - potent biomarkers indicating presence of periodontopathic bacteria.
Periodontitis
A simple, combined fluorogenic and chromogenic method for the assay of proteases in gingival crevicular fluid.
Periodontitis
Activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in human gingiva with chronic marginal periodontitis.
Periodontitis
Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidyl peptidase IV-like activities in gingival crevicular fluid. A comparison of levels before and after basic periodontal treatment of chronic periodontitis patients.
Periodontitis
Correlation between gingivain/gingipain and bacterial dipeptidyl peptidase activity in gingival crevicular fluid and periodontal attachment loss in chronic periodontitis patients. A 2-year longitudinal study.
Periodontitis
Correlation between gingival crevicular fluid dipeptidyl peptidase II and IV activity and periodontal attachment loss. A 2-year longitudinal study in chronic periodontitis patients.
Periodontitis
Detection of cathepsin B- and L-, elastase-, tryptase-, trypsin-, and dipeptidyl peptidase IV-like activities in crevicular fluid from gingivitis and periodontitis patients with peptidyl derivatives of 7-amino-4-trifluoromethyl coumarin.
Periodontitis
Dipeptidyl peptidase II- and IV-like activities in gingival tissue and crevicular fluid from human periodontitis lesions.
Pleural Effusion
Clinical diagnostic utility of adenosine deaminase, interferon-?, interferon-?-induced protein of 10 kDa, and dipeptidyl peptidase 4 levels in tuberculous pleural effusions.
Polymyositis
Muscle breakdown and lysosomal activation (biochemistry).
Prostatic Neoplasms
Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway.
Prostatic Neoplasms
Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.
Renal Insufficiency
Economic Impact of Combining Metformin with Dipeptidyl Peptidase Inhibitors In Diabetic Patients With Renal Failure.
Renal Insufficiency
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Renal Insufficiency, Chronic
Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Renal Insufficiency, Chronic
Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
Renal Insufficiency, Chronic
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Sarcoma
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.
Sepsis
Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study.
Sepsis
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.
Sepsis
The paradox of dipeptidyl peptidase IV inhibition in enterocytic differentiation and epithelial-mesenchymal transition in rat cholestatic sepsis.
Sepsis
Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Shock, Cardiogenic
Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial.
Shock, Cardiogenic
Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more.
Shock, Septic
Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.
Stomach Neoplasms
Polyphyllin I inhibits gastric cancer cell proliferation by downregulating the expression of fibroblast activation protein alpha (FAP) and hepatocyte growth factor (HGF) in cancer-associated fibroblasts.
Stomach Neoplasms
Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer.
Stomach Neoplasms
Stromal fibroblast activation protein alpha promotes gastric cancer progression via epithelial-mesenchymal transition through Wnt/ ?-catenin pathway.
Stomach Neoplasms
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Stroke
Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.
Subarachnoid Hemorrhage
Circulatory dipeptidyl peptidase 3 (cDPP3) is a potential biomarker for early detection of secondary brain injury after aneurysmal subarachnoid hemorrhage.
Thrombocytopenia
Possible prognostic significance of the assessment of dipeptidylpeptidase II in peripheral blood lymphocytes of patients with chronic lymphocytic leukemia.
Thyroid Neoplasms
Decrease in Dipeptidyl Peptidase IV Activity is Linked to the Efficacy of Differentiating Compounds in Follicular Thyroid Carcinoma Cell Lines.
Thyroid Neoplasms
Molecular characterization of the desmoplastic tumor stroma in medullary thyroid carcinoma.
Virus Diseases
Dipeptidyl peptidase I-dependent neutrophil recruitment modulates the inflammatory response to sendai virus infection.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0361
(1R,S)-(2E)-2-(1-fluoro-2-[(2-phenylethyl)amino]ethylidene)cyclopentanecarbonitrile
Homo sapiens
-
IC50: 0.0361 mM, low inhibitory potential against EC 3.4.14.5
0.0404
(1R,S)-(2E)-2-(1-fluoro-2-[(4-fluorobenzyl)amino]ethylidene)cyclopentanecarbonitrile
Homo sapiens
-
IC50: 0.0404 mM, low inhibitory potential against EC 3.4.14.5
0.0329
(1R,S)-(2Z)-2-(1-fluoro-2-[(2-phenylethyl)amino]ethylidene)cyclopentanecarbonitrile
Homo sapiens
-
IC50: 0.0329 mM, low inhibitory potential against EC 3.4.14.5
0.0873
(1R,S)-(2Z)-2-(1-fluoro-2-[(4-fluorobenzyl)amino]ethylidene)cyclopentanecarbonitrile
Homo sapiens
-
IC50: 0.0873 mM, low inhibitory potential against EC 3.4.14.5
0.00013
(3S)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
Homo sapiens
-
-
0.00000088
(3S)-4-[(3aR,6aR)-hexahydrocyclopenta[b]pyrrol-1(2H)-yl]-4-oxobutane-1,3-diamine
Homo sapiens
-
-
0.0000023 - 2.3
(3S)-N1-(4-chlorobenzyl)-4-(2-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
0.62
(3S)-N1-(4-chlorobenzyl)-4-(3-fluoropiperidin-1-yl)-4-oxobutane-1,3-diamine
Homo sapiens
-
IC50: 0.62 nM
0.00000113
(3S)-N1-(4-chlorobenzyl)-4-(3-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
Homo sapiens
-
IC50: 1.13 nM
0.00000039
(3S)-N1-(4-chlorobenzyl)-4-(4-fluoropiperidin-1-yl)-4-oxobutane-1,3-diamine
Homo sapiens
-
IC50: 0.39 nM
0.00000055
(3S)-N1-(4-chlorobenzyl)-4-(4-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
Homo sapiens
-
IC50: 0.55 nM
0.00000048 - 0.0000011
(3S)-N1-(4-chlorobenzyl)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
0.0000547
1-((2S)-2-amino-4-((4-chlorobenzyl)amino)butanoyl)piperidin-3-ol
Homo sapiens
-
IC50: 54.7 nM
0.000113
1-((2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl)piperidin-4-ol
Homo sapiens
-
IC50: 113 nM
0.0000065
1-((2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl)piperidine-2-carbonitrile
Homo sapiens
-
IC50: 6.5 nM
0.0255
1-([(4-fluorobenzyl)amino]acetyl)-2-pyrrolidinecarbonitrile
Homo sapiens
-
IC50: 0.0255 mM
0.00104
1-benzyl-N-(2-cyclohexylidene-2-fluoroethyl)-4-piperidinamine
Homo sapiens
-
IC50: 0.00104 mM, low inhibitory potential against EC 3.4.14.5
0.00104
1-benzyl-N-(2-cyclohexylidene-2-fluoroethyl)piperidin-4-amine
Homo sapiens
-
-
0.0013
1-benzyl-N-(2-cyclopentylidene-2-fluoroethyl)-4-piperidinamine
Homo sapiens
-
IC50: 0.0013 mM, low inhibitory potential against EC 3.4.14.5
0.0031
1-benzyl-N-(2-oxo-2-piperidin-1-ylethyl)piperidin-4-amine
Homo sapiens
-
-
0.0031
1-benzyl-N-[2-oxo-2-(1-piperidinyl)ethyl]-4-piperidinamine
Homo sapiens
-
IC50: 0.0031 mM, low inhibitory potential against EC 3.4.14.5
0.1335
1-[(1-adamantylamino)acetyl]-2-pyrrolidinecarbonitrile
Homo sapiens
-
IC50: 0.1335 mM
0.000004
1-[(2S)-2-amino-4-(benzylamino)butanoyl]piperidine-2-carbonitrile
Homo sapiens
-
IC50: 4.0 nM
0.0000547
1-[(2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl]piperidin-3-ol
Homo sapiens
-
IC50: 54.7 nM
0.000113
1-[(2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl]piperidin-4-ol
Homo sapiens
-
IC50: 113 nM
0.0000065
1-[(2S)-2-amino-4-[(4-chlorobenzyl)amino]butanoyl]piperidine-2-carbonitrile
Homo sapiens
-
IC50: 6.5 nM
0.0000027
3-((3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl)aminomethyl)-benzonitrile
Homo sapiens
-
IC50: 2.7 nM
0.000085
4-oxo-4-(1-piperidinyl)-N1 -(4-piperidinyl)-1,3-(S)-butanedi-amine
Homo sapiens
-
IC50: 85 nM
0.0000008
4-oxo-4-(1-piperidinyl)-N1-(2-thienylmethyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.8 nM
0.00000075
4-oxo-4-(1-piperidinyl)-N1-(4-pyridinylmethyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.75 nM
0.017
4-oxo-4-(1-piperidinyl)-N3-(4-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.017 mM
0.0000009
4-oxo-N1-(2-phenylethyl)-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.9 nM
0.00000191
4-oxo-N1-(3-phenylpropyl)-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.91 nM
0.0015
4-oxo-N1-phenyl-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.0015 mM
0.0046
6-((3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl)amino)nicotinonitrile
Homo sapiens
-
IC50: 0.0046 mM
0.0128
benzyl 4-[(2-cyclohexylidene-2-fluoroethyl)amino]-1-piperidinecarboxylate
Homo sapiens
-
IC50: 0.0128 mM, low inhibitory potential against EC 3.4.14.5
0.0129
N-(1,3-benzodioxol-5-ylmethyl)-2-cyclohexylidene-2-fluoroethanamine
Homo sapiens
-
IC50: 0.0129 mM, low inhibitory potential against EC 3.4.14.5
0.0075
N-(1,3-benzodioxol-5-ylmethyl)-2-cyclopentylideneethanamine
Homo sapiens
-
IC50: 0.0075 mM, low inhibitory potential against EC 3.4.14.5, low inhibitory potential against EC 3.4.14.5
0.0913
N-(2-cyclohexylidene-2-fluoroethyl)-1-adamantanamine
Homo sapiens
-
IC50: 0.0913 mM, low inhibitory potential against EC 3.4.14.5
0.0042
N-(2-cyclohexylidene-2-fluoroethyl)-4-piperidinamine
Homo sapiens
-
IC50: 0.0042 mM, low inhibitory potential against EC 3.4.14.5
0.011
N-(2-cyclohexylidene-2-fluoroethyl)-N-(2-phenylethyl)-amine
Homo sapiens
-
IC50: 0.011 mM, low inhibitory potential against EC 3.4.14.5
0.0219
N-(2-cyclohexylidene-2-fluoroethyl)-N-(4-fluorobenzyl)-amine
Homo sapiens
-
IC50: 0.0219 mM, low inhibitory potential against EC 3.4.14.5
0.0134
N-(2-cyclohexylidene-2-fluoroethyl)-N-(4-methoxybenzyl)amine
Homo sapiens
-
IC50: 0.0134 mM, low inhibitory potential against EC 3.4.14.5
0.1
N-(2-cyclohexylidene-2-fluoroethyl)aniline
Homo sapiens
-
IC50: 0.1 mM, low inhibitory potential against EC 3.4.14.5
0.5
N-(2-cyclohexylidene-2-fluoroethyl)cyclohexanamine
Homo sapiens
-
IC50: 0.5 mM, low inhibitory potential against EC 3.4.14.5
0.0272
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-phenylethyl)amine
Homo sapiens
-
IC50: 0.0272 mM, low inhibitory potential against EC 3.4.14.5
0.0096 - 0.0157
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-pyridinylethyl)amine
0.0108
N-(2-cyclopentylidene-2-fluoroethyl)-N-(4-fluorobenzyl)amine
Homo sapiens
-
IC50: 0.0108 mM, low inhibitory potential against EC 3.4.14.5
0.0155
N-(2-cyclopentylidene-2-fluoroethyl)-N-(4-methoxy-benzyl)amine
Homo sapiens
-
IC50: 0.0155 mM, low inhibitory potential against EC 3.4.14.5
0.09
N-(2-cyclopentylidene-2-fluoroethyl)cyclohexanamine
Homo sapiens
-
IC50: 0.09 mM, low inhibitory potential against EC 3.4.14.5
0.062
N-(2-cyclopentylideneethyl)cyclohexanamine
0.034
N-benzyl-2-cyclohexylidene-2-fluoroethanamine
Homo sapiens
-
IC50: 0.034 mM, low inhibitory potential against EC 3.4.14.5
0.0378
N-benzyl-2-cyclopentylidene-2-fluoroethanamine
Homo sapiens
-
IC50: 0.0378 mM, low inhibitory potential against EC 3.4.14.5
0.026
N-benzyl-2-cyclopentylideneethanamine
0.397
N-benzyl-2-oxo-2-(1-piperidinyl)ethaneamine
Homo sapiens
-
IC50: 0.397 mM, low inhibitory potential against EC 3.4.14.5
0.5
N-benzyl-2-oxo-2-(1-pyrrolidinyl)ethaneamine
Homo sapiens
-
IC50: 0.5 mM
0.0484
N-benzyl-2-thioxo-2-(1-piperidinyl)ethaneamine
Homo sapiens
-
IC50: 0.0484 mM, low inhibitory potential against EC 3.4.14.5
0.177
N-cyclohexyl-2-oxo-2-(1-piperidinyl)ethaneamine
Homo sapiens
-
IC50: 0.177 mM, low inhibitory potential against EC 3.4.14.5
0.276
N-cyclohexyl-2-oxo-2-(1-pyrrolidinyl)ethaneamine
Homo sapiens
-
IC50: 0.276 mM
0.069
N-cyclohexyl-2-thioxo-2-(1-piperidinyl)ethaneamine
Homo sapiens
-
IC50: 0.069 mM, low inhibitory potential against EC 3.4.14.5
0.092
N-cyclohexyl-2-thioxo-2-(1-pyrrolidinyl)ethaneamine
Homo sapiens
-
IC50: 0.092 mM, low inhibitory potential against EC 3.4.14.5
0.052
N-piperonyl-2-oxo-2-(1-piperidinyl)ethaneamine
Homo sapiens
-
IC50: 0.052 mM, low inhibitory potential against EC 3.4.14.5
0.063
N-piperonyl-2-oxo-2-(1-pyrrolidinyl)ethaneamine
Homo sapiens
-
IC50: 0.063 mM, low inhibitory potential against EC 3.4.14.5
0.042
N-piperonyl-2-thioxo-2-(1-piperidinyl)ethaneamine
Homo sapiens
-
IC50: 0.042 mM, low inhibitory potential against EC 3.4.14.5
0.067
N-piperonyl-2-thioxo-2-(1-pyrrolidinyl)ethaneamine
Homo sapiens
-
IC50: 0.067 mM, low inhibitory potential against EC 3.4.14.5
0.0015
N-[3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl]acetamide
Homo sapiens
-
IC50: 0.0015 mM
0.0018
N-[3-(S)-amino-4-oxo-4-(1-piperidinyl)butyl]guanidine bis-(trifluoroacetate)
Homo sapiens
-
IC50: 0.0018 mM
0.0074
N-[3-amino-1-(S)-(1-piperidinylcarbonyl)propyl]guanidine bis-(trifluoroacetate)
Homo sapiens
-
IC50: 0.0074 mM
0.0074
N-[3-amino-4-oxo-4-(1-piperidinyl)butyl]benzamide
Homo sapiens
-
IC50: 0.0074 mM
0.0537
N1 -(2-cyclopentylidene-2-fluoroethyl)-N3,N3-dimethyl-1,3-propanediamine
Homo sapiens
-
IC50: 0.0537 mM, low inhibitory potential against EC 3.4.14.5
0.00000066
N1 -(4-methoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.66 nM
0.0000042
N1,N1-di(4-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 4.2 nM
0.0000006
N1,N1-dibenzyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.6 nM
0.00000131
N1-(1-naphthylmethyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.31 nM
0.0000027
N1-(2,4-dimethoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 2.7 nM
0.00000023
N1-(2-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.23 nM
0.0546
N1-(2-cyclohexylidene-2-fluoroethyl)-N3,N3-dimethyl-1,3-propanediamine
Homo sapiens
-
IC50: 0.0546 mM, low inhibitory potential against EC 3.4.14.5
0.00000185
N1-(2-methoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.85 nM
0.0000011
N1-(2-naphthylmethyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.1 nM
0.00000134
N1-(3-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.34 nM
0.00000177
N1-(3-methoxybenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.77 nM
0.0235
N1-(3-nitro-2-pyridinyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.0235 mM
0.00000048
N1-(4-chlorobenzyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.48 nM
0.00000022
N1-(4-chlorobenzyl)-N1-methyl-4-oxo-4-(1-piperidinyl)-1,3-butanediamine
Homo sapiens
-
IC50: 0.22 nm
0.0000011
N1-(cyclohexylmethyl)-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 1.1 nM
0.00000203
N1-benzyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 2.03 nM
0.0000186
N1-cyclohexyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 18.6 nM
0.00000039
N1-[2-(benzyloxy)benzyl]-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.39 nM
0.00000041
N1-[4-(benzyloxy)benzyl]-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine
Homo sapiens
-
IC50: 0.41 nM
0.0038
N2-cyclopentyl-N-[(diphenoxyphosphoryl)(phenyl)methyl]glycinamide
Homo sapiens
-
-
0.0125
N3-benzyl-4-oxo-4-(1-piperidinyl)-1,3-(S)-butanediamine dihydrobromide
Homo sapiens
-
IC50: 0.0125 mM
0.00000048
[(1R)-1-[[(2S)-2,4-diaminobutanoyl]amino]pentyl]boronic acid
Homo sapiens
-
-
0.0000023
(3S)-N1-(4-chlorobenzyl)-4-(2-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
Homo sapiens
-
IC50: 2.3 nM
2.3
(3S)-N1-(4-chlorobenzyl)-4-(2-methylpiperidin-1-yl)-4-oxobutane-1,3-diamine
Homo sapiens
-
IC50: 2.3 mM
0.00000048
(3S)-N1-(4-chlorobenzyl)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
Homo sapiens
-
-
0.0000011
(3S)-N1-(4-chlorobenzyl)-4-oxo-4-piperidin-1-ylbutane-1,3-diamine
Homo sapiens
-
IC50: 1.1 nM
0.0096
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-pyridinylethyl)amine
Homo sapiens
-
IC50: 0.0096 mM, low inhibitory potential against EC 3.4.14.5
0.0157
N-(2-cyclopentylidene-2-fluoroethyl)-N-(2-pyridinylethyl)amine
Homo sapiens
-
IC50: 0.0157 mM, low inhibitory potential against EC 3.4.14.5
0.062
N-(2-cyclopentylideneethyl)cyclohexanamine
Homo sapiens
-
IC50: 0.062 mM
0.062
N-(2-cyclopentylideneethyl)cyclohexanamine
Homo sapiens
-
IC50: 0.062 mM, low inhibitory potential against EC 3.4.14.5, low inhibitory potential against EC 3.4.14.5
0.026
N-benzyl-2-cyclopentylideneethanamine
Homo sapiens
-
IC50: 0.026 mM
0.026
N-benzyl-2-cyclopentylideneethanamine
Homo sapiens
-
IC50: 0.026 mM, low inhibitory potential against EC 3.4.14.5, low inhibitory potential against EC 3.4.14.5
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.